Vitamin B treats fatty liver – | Iranian and world news

About 5 percent of the world’s population suffer from “Metabolic Disorders Liver Liver” (MSLD), according to . It lacks treatments that are accurately targeted. Researchers have now identified a genetic factor that exacerbates the disease, and interestingly, a drug approved by the US Food and Drug Administration that effectively is the target is vitamin B2.

A research in collaboration with Professor Jang Hyun Choi of the National Institute of Science and Technology (UlsanUnist), Hawayang Yun of Pharmacy College and Institute of Drug Development Research at the National University of Pusan ​​and Neoung Hua Park from the University of Ulsan Hospital, which is secreted in the liver as a genetic factor in the progression of the “metabolic fatty liver disorder”.

MIR-1 is a special RNA molecule expressed in hepatocytes (a type of liver cell) and helps suppress the expression of specific genes that are targeted. Researchers found an abnormal increase in MIR-1 levels in human patients with fatty liver and laboratory animals. Using molecular analysis, they have shown that the MIR-1, by preventing the expression of Sirt 2 gene, leads to fat, inflammation and fibrosis. Sirt2 is a gene that is involved in fat metabolism in liver cells.

The researchers used genetic modification methods to stop the production of MIR-1 in mice and saw a significant decrease in liver fat aggression along with improving insulin sensitivity and liver function markers.

In addition, the study of the US Food and Drug Administration’s approved drugs showed that Vitamin B2 is the most effective substance in MIR-1 repression. In the mice treated with this drug, a significant reduction in the MIR-2 liver levels and increased Sirt2 activity were observed. The activated Sirt2 gene revived the previously disrupted fat metabolism paths, so the liver fat balance became normal.